|
42 documents found matching dt:presentation.
|
|
of 5
Prev
Next
|
|
|
|
Showing 1-10 of 42 documents
|
1.
Presentation re: dodge ball
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
DODGE!
PLAINTIFF'S EXHIBIT
5
Confidential - Subject To Protective Order
MRK-AAR0019773
pgNbr=1
oxx
(rofecoxib)
it
I am concerned with the potentia edema that occurs with Vioxx."
Confidential - Subject To Protective Order
MRK-AAR00Ì9774
pgNbr=2
®
(ïofecoxib)
li
am concerned with dose-related increases in hypertension with Vioxx."
Confidential - Subject To Protective Order
MRK-AAR0019775
pgNbr=3
allÄ O °
- . .-./_y,ti^tj.r-Äi^._-.-Ä
li
Can Vioxx be used in patients using low dose aspirin?"
Confidential - Subject To Protective Order
MRK-AAR0019776
pgNbr=4
\i UiVWAIL//
I am concerned about the cardiovascular effects of Vioxx?"
Confidential - Subject To Protective Order
MRK-AARQ019777
pgNbr=5
(rofecoxib)
The competition has been in my
office telling me that the incidence
of heart attacks is greater with
Vioxx than Celebrex."
Confidential - Subject To Protective Order
MRK-AAR0019778
pgNbr=6
I fCìTarcs vi hi \ì \JIKZ\~kjMui
There is no difference between Vioxx and Celebr
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx10p10
|
|
| |
2.
Presentation: Advantage
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Merck & Co.
|
|
Search Terms in Context:
|
ADVANTAGE
^" IOXX™(rofecoxib) Assessment of the Differences Between VIOXX and Naproxen To Ascertain Gastrointestinal Tolerablllty and Effectiveness
Confidential - Subject To Protective Order
(PLAINTIFF'S » EXHIBIT
MRK-ADI0017766
pgNbr=1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx03m10
|
|
| |
3.
Presentation re dodge ball
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
(rofecoxib)
DODGE!
MRK-AAR0019773
pgNbr=1
(rofecoxib)
"l am concerned with the potential edema that occurs with Vioxx."
MRK-AAR0019774
pgNbr=2
(rofecoxib)
a
am concerned with dose-related increases in hypertension with Vioxx."
MRK-AAR0019775
pgNbr=3
(rofecoxib)
"Can Vioxx be used in patients using low dose aspirin?"
MRK-AAR0019776
pgNbr=4
(rofecoxib)
--"¦¦ T^&^*£jì$t^g£,
I am concerned about the cardiovascular effects of Vioxx?"
MRK-MR0019777
pgNbr=5
(rofecoxib)
"The competition has been in my
office telling me that the incidence
of heart attacks is greater with
Vioxx than Celebrex."
MRK-AAR0019778
pgNbr=6
(rofecoxib)
There is no difference between Vioxx and Celebrex, why should I use Vioxx?"
MRK-AAR0019779
pgNbr=7
'ri
¦ -,.* : v^
(rofecoxib)
Vioxx cannot be used for longer than five days when treating patients for acute pain?"
MRK-AAR0019780
pgNbr=8
(rofecoxib)
r.. —,T7 -.¦ rr.rjr/JS'T'jr ìSTa??!" t?
I use Celebrex. I'm concerned about the safety profile with Vio
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx05d10
|
|
| |
4.
MVX for Vioxx
|
Document Date:
|
20011001
|
|
Search Terms in Context:
|
FINAL
MVX for VIOXX
DWA to USHH field sales force
10/01/01
Hello everyone. This is David Anstice with a MVX going to the entire Field Sales Force. I realize you don't typically hear directly from me, but this message is one that is so important that I felt compelled to deliver it myself.
I know you've been working hard on territory, especially during times like this. You've been conducting business that may not quite feel like "business as usual," and I know you're doing your best. I can't tell you enough how much I appreciate you hanging in there. You've been focused on a "higher calling" of helping physicians and patients and it's along those lines that I'd like to talk to you today about VIOXX.
As all of you know, Merck received a Warning Letter on VIOXX from the FDA. You received a MVX from Jo Jerman alerting you to this issue and yesterday you received a bulletin giving directions on how to respond to questions from customers about it. I have all the confidence in the world that you'll adhere to th
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17s10
|
|
| |
5.
MVX for Vioxx
|
Document Date:
|
20011010
|
|
Search Terms in Context:
|
Draft-Revised 10-10-01
MVX for VIOXX
DWA to USHH field sales force
10/10/01
Hello everyone. This is David Anstice with a MVX going to the entire Field Sales Force. I realize you don't typically hear directly from me, but this message is one that is so important that I felt compelled to deliver it myself.
As all of you know, Merck received a Warning Letter on VIOXX from the FDA. You received several bulletins giving you direction on issues raised in the letter and directions on bow to respond to questions from customers about it. It is important that you follow these directions. I also want to remind you how important it is to promote our products in conformance with Merck Policy Letters and consistent with the approved product labeling for them. I have all the confidence in the world that you'll adhere to those directions.
I'd like to close by saying that you've heard us say many times lately that Merck firmly stands behind the overall and cardiovascular safety of VIOXX and we continue to affirm this wi
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17r10
|
|
| |
6.
Remarks by Gilmartin -- strategic decisions conference
|
Document Date:
|
20000607
|
|
Search Terms in Context:
|
Remarles by Raymond V. Gilmarfin
Sanford Bernstein Strategic Decisions Conference
Plaza Hotel, New York
Wednesday, June 7,2000
At Merck, our strategy for growth is based on breakthrough research and demonstrating the value of our medicines. It's straightforward - and it works. Since mid-1996, we have been saying that our new medicines and our in-line products would have the potential to offset upcoming patent expirations.
We're right on target: fifteen new medicines successfully launched since 1995 alone, and a strong pipeline - five new medicines in Phase lib and HI, two new vaccines in clinical trials, and several new mechanism treatments in early development. As Ed Scolnick, head of Merck research, told our shareholders at our annual meeting in April, this is the most productive time in the history of Merck research. So we're confident in our ability to deliver earnings growth rates competitive with the other leading health care companies through the year 2002. And we're confident in our long-term goa
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx05m10
|
|
| |
| 7.
Key Marketing Messages HHPAC
|
| |
8.
VIGOR Preliminary Results Slides
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Confidential - Subject To Protective Order
MRK-ABK0011052
pgNbr=1
Confidential - Subject To Protective Order
MRK-ABK0011053
pgNbr=2
Nonsteroidal anti-inflammatory drugs (NSAIDs) nonselectiveiy inhibit Cyclooxygenase 1 and 2 (COX-1 and CÖX-2)
Inhibition of COX-2 provides the analgesic and anti-inflammatory properties of NSAIDS
Inhibition of CÖX-1 results in the Gastrointestinal (Gl) toxicity of NSAIDs
A COX-2 specific inhibitor will be an effective anti-inflammatory and analgesic medication with substantially reduced Gl toxicity compared with NSAIDs, .
Confidential - Subject To Protective Order
MRK-ABK0011054
pgNbr=3
Confidential - Subject To Protective Order
MRK-ABK0011055
pgNbr=4
Confidential - Subject To Protective Order
MRK-ABK0011056
pgNbr=5
Confidential - Subject To Protective Order
MRK-ABK0011057
pgNbr=6
Confidential - Subject To Protective Order
MRK-ABK0011058
pgNbr=7
Confidential - Subject To Protective Order
MRK-ABK0011059
pgNbr=8
Confidential - Subject To Protective Ord
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx14e10
|
|
| |
9.
Remarks at Vioxx launch meeting
|
Document Date:
|
19990524
|
|
Search Terms in Context:
|
evolved since its approval. But best of all, we've gotten feedback from our consulting physicians on our approach and presentation of the Vioxx data. And I'm not exaggerating when I tell you that feedback on our scientific excellence and balanced approach has been very, very positive.
Reason number seven - Our specialty representatives have not only reached, theyVe surpassed their target
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx05s10
|
|
| |
10.
Merck Slide Show Presentation to FDA Advisory Committee
|
Document Date:
|
20010208
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
FDA Arthritis Advisory Committee
February 8, 2001
VIOXX™ Gastrointestinal Outcomes Research Trial
(VIGOR)
Bonnie Goldmann, M.D.
Regulatory Affairs
Merck Research Laboratories
pgNbr=1
Cyclooxygenases
Arachidonic Acid
>.';>Ä:>?»»»r.->x->>»>>'/ir»;
C02H
Protection of Gastric Mucosa f Platelet Function
¦twsää&wsss
Gastropathy and Antithrombotic Effects
NSAIDs
iBlIlllBIPl
WÊËÈÊÊœÊÊÊÊËÊÈÊÊÈ
I
Effects on Na+ Balance
Anti-inflammatory and Analgesie Effects
2
pgNbr=2
NSAID Gastropathy
• One of the most common serious drug-related adverse events are NSAID-related serious upper Gl side effects
• Estimated to result in 103,000 hospitalizations and 16,500 deaths per year in the US*
*Wolfe.üchtenstein,Sinqh, NEJM 340:1888-1899, [19991.
pgNbr=3
Cyclooxygenases
¦ »-"T >>>-rti V.><^0'^> ¦-
Arachidonic Acid
fRifiWrW^W-'
C02H
Selective COX-2 Inhibitors
*mmm
Anti-inflammatory and Analgesic Effects
pgNbr=4
COX-2 Hypothesis
• Selective COX-2 inhibitor should demonstrate:
1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx01j10
|
|
| |
|
Prev
Next
|
